Ankündigung • May 03
Novo Integrated Sciences Receives Notice from Nasdaq As previously reported, The Nasdaq Stock Market LLC’s (“Nasdaq”) Listing Qualifications Staff (the “Staff”) notified Novo Integrated Sciences, Inc. (the “Company”) that it was in violation of the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Also as previously disclosed, on November 4, 2024, the Company received a letter from Nasdaq indicating that the Company’s common stock would be delisted from Nasdaq and trading in the Company’s common stock would be suspended at the open of trading on November 6, 2024. Beginning at the open of trading on November 6, 2024, the Company’s common stock began trading on the OTC Market under the symbol “NVOS.” On April 28, 2025, Nasdaq notified the Company that it would file a Form 25 with the Securities and Exchange Commission to complete the delisting of the Company’s common stock. As of the filing time of this Current Report on Form 8-K, the Form 25 has not yet been filed by Nasdaq. The delisting will be effective 10 days after the Form 25 is filed. The Company’s common stock will continue to be quoted on the OTC Market following filing and effectiveness of the Form 25. Ankündigung • Jan 15
Novo Integrated Sciences, Inc. announced delayed 10-Q filing On 01/14/2025, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Ankündigung • Dec 20
Novo Integrated Sciences, Inc. Auditor Raises 'Going Concern' Doubt Novo Integrated Sciences, Inc. filed its 10-K on Dec 18, 2024 for the period ending Aug 31, 2024. In this report its auditor, Fruci & Associates II, PLLC, gave a qualified opinion expressing doubt that the company can continue as a going concern. Ankündigung • Nov 30
Novo Integrated Sciences, Inc. announced delayed annual 10-K filing On 11/29/2024, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Ankündigung • Nov 08
Novo Integrated Sciences, Inc.(OTCPK:NVOS) dropped from S&P TMI Index Novo Integrated Sciences, Inc.(OTCPK:NVOS) dropped from S&P TMI Index Ankündigung • Sep 30
Novo Integrated Sciences, Inc., Annual General Meeting, Nov 22, 2024 Novo Integrated Sciences, Inc., Annual General Meeting, Nov 22, 2024. Ankündigung • Aug 16
Novo Integrated Sciences Intends to Request Hearing Before Nasdaq Hearing Panel On February 9, 2024, Novo Integrated Sciences, Inc. (the ‘Company’) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (‘Common Stock’), for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share (the ‘Minimum Bid Price Requirement’) for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the ‘Original Notice’). At that time, the Company was provided a compliance period of 180 calendar days from the date of the Original Notice, or until August 7, 2024, to regain compliance with the Minimum Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). As the Company did not regain compliance with the Minimum Bid Price Requirement by August 7, 2024, and it was determined by the Nasdaq Staff that the Company should not be eligible for another 180 calendar-day extension, the Company received a delisting determination letter on August 9, 2024. Accordingly, the Company intends to timely request a hearing before a Nasdaq Hearing Panel (‘Panel’). The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension period not to exceed February 5, 2025. However, there can be no assurance that the Panel will grant the Company an additional extension period or that the Company will ultimately meet all applicable requirements for continued listing on The Nasdaq Capital Market. The Company intends to provide a plan to regain compliance to the Panel. Ankündigung • Jul 16
Novo Integrated Sciences, Inc. announced delayed 10-Q filing On 07/15/2024, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Ankündigung • Jun 15
Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) acquired Ophir Collection, Llc. Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) acquired Ophir Collection, Llc on June 13, 2024.Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) completed the acquisition of Ophir Collection, Llc on June 13, 2024. Reported Earnings • Apr 17
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.58 loss in 2Q 2023) Second quarter 2024 results: US$0.16 loss per share (improved from US$0.58 loss in 2Q 2023). Revenue: US$3.17m (up 24% from 2Q 2023). Net loss: US$2.75m (loss narrowed 41% from 2Q 2023). Ankündigung • Feb 17
Novo Integrated Sciences, Inc. Announces Executive Changes Novo Integrated Sciences, Inc. announced Mr. Robert Oliva has been appointed as the Company’s new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company’s Chief Operating Officer and as a member of the Company’s Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company’s product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. On February 15, 2023, Christopher David, the Company’s President, Chief Operating Officer and member of the Board of Directors of Novo Integrated Sciences, Inc. (“Novo” and, the “Company”) informed the Company of his decision to voluntarily resign from his position as the Company’s President effective as of February 15, 2024. Mr. David did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Oliva previously served the Company between January 26, 2021 and June 30, 2022 in the role of Director. During his time as Director, Mr. Oliva has also served the Company as a member of the Compensation Committee and Nominating and Corporate Governance Committees. On June 30, 2022, Mr. Oliva resigned from the Board of Directors. Mr. Oliva is not currently party to an employment agreement with the Company, nor is there any current compensation arrangement, however Mr. Oliva and the Company plan to enter into an Employment Agreement. Robert “Rob” Oliva, 60, is the owner of Toronto based Venture Metal Works, a leading mid-market enterprise which specializes in architectural and structural steel design, fabrication and manufacturing for the construction industry throughout Canada. Prior to founding Venture Metal Works in 2011, for 28 years Mr. Oliva worked for, and ultimately became the owner of, Tor Steel Company Limited, which provided architectural and structural steel products for the Canadian based construction industry. For over 40 years, Mr. Oliva has developed proven expertise in delivering system and operational efficiency while managing aggressive, yet sustainable growth. As a successful business owner, he brings the Company a wealth of knowledge in areas related to implementing efficient operational strategy, developing system processes, supply-chain management, and sales. Mr. Oliva’s proven business development success provides the Company with the ability to determine the optimal balance of both present activity and future vision and its direct impact on the Company’s strategic direction and priorities. Ankündigung • Feb 16
Novo Integrated Sciences, Inc. Receives A Notification Letter from the Nasdaq Stock Market, LLC On February 9, 2024, Novo Integrated Sciences, Inc., a Nevada corporation (the Company"), received a notification letter (the Notification Letter") from The Nasdaq Stock Market, LLC (Nasdaq") that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq. Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock between December 27, 2023, and February 8, 2024, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market under the symbol NVOS." The Notification Letter provides that the Company has 180 calendar days, or until August 7, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by August 7, 2024, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirements (except for the bid price requirement) and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company's common stock, at which point the Company will have an opportunity to appeal the delisting determination to a hearings panel. The Company intends to monitor the closing bid price of its common stock and will consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Ankündigung • Jan 17
Novo Integrated Sciences, Inc. announced delayed 10-Q filing On 01/16/2024, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Ankündigung • Nov 30
Novo Integrated Sciences, Inc. announced delayed annual 10-K filing On 11/29/2023, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Ankündigung • Nov 07
Novo Integrated Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement Novo Integrated Sciences, Inc. announced that the company will undertake a reverse stock split of its common stock at a ratio of 1-for-10 (the ‘Reverse Stock Split’). The reverse stock split is expected to become effective immediately after the close of trading on the Nasdaq Capital Market (‘Nasdaq’) on November 6, 2023 (the ‘Effective Date’) and the company’s common stock is expected to begin trading on Nasdaq on a Reverse Stock Split-adjusted basis on November 7, 2023, under the new CUSIP number, 67011T300. Robert Mattacchione, Novo’s Chief Executive Officer and Chairman of the Board, stated, “Although we have been investigating various strategies to regain compliance with Nasdaq's minimum bid price requirement, we believe that effectuating a reverse stock split is the most appropriate course of action at this time. We believe that by promptly addressing the uncertainty regarding our listing we will be better positioned to maximize value for our shareholders.” Stockholder approval for the Reverse Stock Split was obtained at the Company's annual meeting of stockholders on September 29, 2023. After careful consideration in light of current market conditions, the Company's Board of Directors approved the Reverse Stock Split ratio of 1-for-10. The Company believes maintaining its Nasdaq listing will situate Novo more favorably and potentially attract a broader group of institutional and retail investors. Ankündigung • Oct 25
Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) announces an Equity Buyback for $5 million worth of its shares. Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) announces a share repurchase program. Under the program, the company will repurchase up to $5 million worth of its outstanding common stock. Ankündigung • Sep 14
Novo Integrated Sciences, Inc.'s IoNovo for Kids receives Registration Number and Regulatory Approval by Turkey’s Ministry of Health Novo Integrated Sciences, Inc. announced that its IoNovo for Kids pure iodine oral spray has been granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined to be safe, effective, of high quality, and eligible for sale in Turkey. With this registration, Novo’s two IoNovo Iodine related products have full approval for distribution and sale throughout Turkey. Novo has partnered with NOYEM Global Foreign Trade and Consultancy Inc. Phase 1 of NOYEM’s plan provides for 3 separate distribtuion and sales channels including (i) doctors at over 100 different institutions in approximately 40 different cities across Turkey including govermental, university, and private hospitals; (ii) pharmaceutical wholesalers that serve approximately 15,000 pharmacies; and (iii) e-commerce platforms including Turkey’s larger e-commerce platform with approximately 30 million active members. Additionally, Iodine is known to promote healthy skin, nails, and hair. IoNovo Iodine is directly absorbed into the bloodstream through a precise oral spray dosage without interacting with the oral micro-biome or any bacteria or viruses. All of Novo’s IoNovo products are designed to be delivered via oral spray which is proven to be significantly more effective in absorption than pill or gel capsules. Ankündigung • Aug 23
Novo Integrated Sciences, Inc.’ IoNovo Iodine Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health Novo Integrated Sciences, Inc. announced that its IoNovo Iodine product has been granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined to be safe, effective, of high quality, and eligible for sale in Turkey. For decades, the global medical community has recognized Iodine as an essential micronutrient that assists the thyroid to produce T3 and T4 hormones needed for a healthy metabolism, immune system, increased energy levels, and cognitive development, Additionally, Iodine is known to promote healthy skin, nails, and hair. IoNovo Iodine is directly absorbed into the bloodstream through a precise oral spray dosage without interacting with the oral micro-biome or any bacteria or viruses. All of Novo’s IoNovo products are designed to be delivered via oral spray which is proven to be significantly more effective in absorption than pill or gel capsules. Ankündigung • Aug 19
Novo Integrated Sciences, Inc., Annual General Meeting, Sep 29, 2023 Novo Integrated Sciences, Inc., Annual General Meeting, Sep 29, 2023, at 13:00 US Eastern Standard Time. Agenda: To elect five directors nominated by Novo’s Board of Directors, based on the recommendation of Novo’s independent directors, to serve for a one-year term following approval by the stockholders at the Annual Meeting; to approve the 2023 Equity Incentive Plan; to approve the amendment of Novo’s Amended and Restated Articles of Incorporation, as amended, to effectuate a reverse stock split of Novo’s outstanding shares of common stock, at a ratio of no less than 1-for-5 and no more than 1-for-15, with such ratio to be determined at the sole discretion of the Board; to ratify the appointment of Fruci & Associates II, PLLC as Novo’s independent registered public accounting firm for the fiscal year ending August 31, 2023; and to transact such other business as may properly come before the Annual Meeting and/or any adjournment or postponement thereof. New Risk • Jul 19
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: US$1.1m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 68% per year over the past 5 years. Shareholders have been substantially diluted in the past year (376% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$1.1m revenue). Market cap is less than US$100m (US$17.3m market cap). Reported Earnings • Jul 18
Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.13 loss in 3Q 2022) Third quarter 2023 results: US$0.01 loss per share (improved from US$0.13 loss in 3Q 2022). Net loss: US$1.50m (loss narrowed 61% from 3Q 2022). Over the last 3 years on average, the company's earnings growth rate has exceeded its share price growth rate by 4 percentage points per year. Ankündigung • Jul 13
Novo Integrated Sciences, Inc. Appoints Vivek Sethi as Principal Financial Officer On July 7, 2023, the Board of Directors of Novo Integrated Sciences, Inc. appointed Vivek Vik" Sethi, as the Company's Principal Financial Officer. Mr. Sethi will also serve as the Company's principal accounting officer. Vivek Vik" Sethi, CPA, CA, age 37, brings over 13 years of international corporate finance and operational experience, directing accounting and finance functions, business and personal tax compliance and planning, internal and external reporting, and the ongoing evaluation and analysis of corporate financial activity. In 2017, Mr. Sethi founded Tax Wave Solutions, located in Brampton Ontario Canada, which provides a wide range of services, to both businesses and individuals, such as accounting, bookkeeping, payroll processing, tax compliance and filings, audit support, advisory, and business consultancy. Previously, Mr. Sethi founded Vivek Sethi & Associates in India, which provided accounting services such as tax planning, auditing of small and medium-sized businesses, tax return filings, financial reports and providing solutions to tax related queries. Mr. Sethi subsequently sold the business and moved to Canada. Mr. Sethi holds a Canadian CPA designation and a Chartered Accountant designation from The Institute of Chartered Accountants of India. He graduated with a B.Com from Punjab University in Ludhiana, India. Reported Earnings • May 26
First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.067 loss in 1Q 2022) First quarter 2023 results: US$0.12 loss per share (further deteriorated from US$0.067 loss in 1Q 2022). Revenue: US$3.42m (up 8.1% from 1Q 2022). Net loss: US$3.94m (loss widened 118% from 1Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. Board Change • Apr 17
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 1 highly experienced director. COO, President & Director Chris David is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Ankündigung • Feb 01
Novo Integrated Sciences Announces Receipt of Notice from Nasdaq Novo Integrated Sciences, Inc. (the “Company” or “Novo”), reported that it received a notice on January 25, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended August 31, 2022 (the “Form 10-K”) and its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2022 (the “Form 10-Q”). The Company previously disclosed that it received a notice from Nasdaq on December 15, 2022 advising the Company that it was not in compliance with Rule 5250(c)(1) as a result of its failure to timely file the Form 10-K. Under Nasdaq rules, the Company has 60 calendar days from receipt of Nasdaq’s December 2022 notice, or until February 13, 2023, to submit a plan to regain compliance with Rule 5250(c)(1). If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-K, or until June 12, 2023, to regain compliance. The Company intends to file the Form 10-K and the Form 10-Q as promptly as possible in order to regain compliance with Rule 5250(c)(1). However, if the Company does not submit the Form 10-K and the Form 10-Q by February 13, 2023, the Company will submit a plan by such date to Nasdaq that outlines, as definitively as possible, the steps the Company will take to promptly file the Form 10-K and/or the 10-Q, as applicable, and regain compliance. Ankündigung • Jan 18
Novo Integrated Sciences, Inc. announced delayed 10-Q filing On 01/17/2023, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Ankündigung • Dec 23
Novo Integrated Sciences Announces Receipt of Notice from Nasdaq Novo Integrated Sciences, Inc. (the “Company” or “Novo”) reported that it received a notice (the “Notice) on December 15, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended August 31, 2022 (the “Form 10-K”). Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice or until February 13, 2023, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-K, or until June 12, 2023, to regain compliance. In response to the Notice, the Company intends to file the Form 10-K as promptly as possible in order to regain compliance with the Rule. However, if the Company does not submit the Form 10-K by February 13, 2023, the Company will submit a plan by such date to Nasdaq that outlines, as definitively as possible, the steps the Company will take to promptly file the Form 10-K and regain compliance. Ankündigung • Nov 30
Novo Integrated Sciences, Inc. announced delayed annual 10-K filing On 11/29/2022, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Ankündigung • Nov 28
Novo Integrated Sciences Receives A Notification Letter from Nasdaq Regarding Minimum Bid Price Requirements On November 21, 2022, Novo Integrated Sciences, Inc. received a notification letter ("the Notification Letter") from The Nasdaq Stock Market, LLC ("Nasdaq") that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq. Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock between October 10, 2022 and November 11, 2022, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market under the symbol NVOS". The Notification Letter provides that the Company has 180 calendar days, or until May 22, 2023, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by May 22, 2023, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirements (except for the bid price requirement) and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the delisting determination to a hearings panel. The Company intends to monitor the closing bid price of its common stock and will consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 1 highly experienced director. COO, President & Director Chris David is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Ankündigung • Oct 15
Novo Integrated Sciences, Inc. has completed a Composite Units Offering in the amount of $2 million. Novo Integrated Sciences, Inc. has completed a Composite Units Offering in the amount of $2 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 4,000,000
Price\Range: $0.5
Discount Per Security: $0.035 Reported Earnings • Jul 15
Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.016 loss in 3Q 2021) Third quarter 2022 results: US$0.13 loss per share (down from US$0.016 loss in 3Q 2021). Revenue: US$13.9m (up 482% from 3Q 2021). Net loss: US$3.81m (loss widened US$3.40m from 3Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance. Ankündigung • Jul 12
Novo Integrated Sciences, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2022 Novo Integrated Sciences, Inc. provided revenue guidance for the third quarter of fiscal year 2022. For the quarter, the company's revenue is expected to be in the range of $13.4 million to $13.9 million, an increase of approximately 367% to 384%, as compared to the second quarter of fiscal year 2022, and an increase of approximately 463% to 484%, as compared to the third quarter of fiscal 2021. The company’s strong revenue performance in the third quarter was driven primarily by an increase in both proprietary and outsourced product sales. Board Change • Apr 27
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). COO, President & Director Chris David is the most experienced director on the board, commencing their role in 2014. Independent Director Michael Pope was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 14
Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.056 loss in 2Q 2021) Second quarter 2022 results: US$0.17 loss per share (down from US$0.056 loss in 2Q 2021). Revenue: US$2.87m (up 38% from 2Q 2021). Net loss: US$4.81m (loss widened 259% from 2Q 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance. Board Change • Apr 14
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). COO, President & Director Chris David is the most experienced director on the board, commencing their role in 2014. Independent Director Michael Pope was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Ankündigung • Jan 16
Novo Integrated Sciences, Inc. announced delayed 10-Q filing On 01/14/2022, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Ankündigung • Nov 30
Novo Integrated Sciences, Inc. announced delayed annual 10-K filing On 11/29/2021, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Ankündigung • Aug 31
Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) agreed to acquire Seven Pharmacies in the United States. Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) agreed to acquire Seven Pharmacies in the United States on August 30, 2021. The proposed all-stock transactions contemplate the acquisition, by Novo, of a 50% interest in each pharmacy. This acquisition of seven pharmacies, which collectively generated approximately $55 million in annualized revenue in 2020. Novo expects to negotiate and enter into definitive agreements and to close the acquisitions during the second half of 2021. Reported Earnings • Jul 16
Third quarter 2021 earnings released: US$0.016 loss per share (vs US$0.004 loss in 3Q 2020) The company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: US$2.38m (up 129% from 3Q 2020). Net loss: US$411.2k (loss widened 318% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings. Executive Departure • Jun 25
Principal Financial Officer & Principal Accounting Officer Sterling Jimenez has left the company On the 15th of June, Sterling Jimenez's tenure as Principal Financial Officer & Principal Accounting Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Sterling's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.96 years. Executive Departure • Apr 25
Principal Financial Officer & Principal Accounting Officer has left the company On the 20th of April, Thomas Bray's tenure as Principal Financial Officer & Principal Accounting Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Thomas' name. A total of 2 executives have left over the last 12 months. Reported Earnings • Apr 17
Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.022 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$2.08m (down 14% from 2Q 2020). Net loss: US$1.34m (loss widened 166% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings. Ankündigung • Jan 29
Novo Integrated Sciences Announces Three New Independent Directors Appointments to Its Board of Directors and Formation of an Audit Committee Novo Integrated Sciences, Inc. announced that it has increased the size of the Company’s Board of Directors (the “Board”) from 4 to 7 members and appointed Michael Pope, Robert Oliva, and Alex Flesias as directors of the Company. These three individuals have also been appointed to serve on the Company’s newly formed Audit Committee, with Mr. Pope being the Committee Chairman. All three have joined the Board and Audit Committee effective January 26, 2021. Michael Pope serves as the CEO and Chairman at Boxlight Corporation. Robert “Rob” Oliva is the owner of Toronto based Venture Metal Works. Alex Flesias, B.A., LLB has been a partner at Hammond Flesias Law Firm in Toronto, Canada since 2007. Ankündigung • Dec 23
Novo Integrated Sciences, Inc. Announces Executive Changes On December 15, 2020, Klara Radulyne notified Novo Integrated Sciences, Inc. of her intent to resign as the Company's Principal Financial Officer, effective December 15, 2020. On December 15, 2020, Company's Board of Directors appointed Thomas Bray as the Company's Principal Financial Officer. Mr. Bray will also serve as the Company's principal accounting officer. Mr. Bray, age 56, has served as the Controller for Novo Healthnet Limited, since October 2020, managing all accounting and finance functions, including all external and internal reporting. Ankündigung • Dec 01
Novo Integrated Sciences, Inc. announced delayed annual 10-K filing On 11/30/2020, Novo Integrated Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 
